Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 800 shares of the stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $13.83 per share, for a total transaction of $11,064.00. Following the completion of the purchase, the insider directly owned 830,584 shares in the company, valued at $11,486,976.72. The trade was a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The shares were purchased at an average price of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The shares were purchased at an average price of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc acquired 120,804 shares of Rallybio stock. The shares were purchased at an average price of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Price Performance

Rallybio stock opened at $14.35 on Thursday. The firm has a market capitalization of $75.91 million, a PE ratio of -5.61 and a beta of -1.10. The company’s 50-day moving average is $9.70 and its 200-day moving average is $6.93. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $15.31.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.23 million.

Analyst Ratings Changes

A number of research analysts recently commented on RLYB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Trading of Rallybio

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the period. XTX Topco Ltd boosted its holdings in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the period. Susquehanna International Group LLP boosted its holdings in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the period. Renaissance Technologies LLC boosted its holdings in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the period. Institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.